Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Why Paul Prescott Is Watching Aditxt, Inc. (Nasdaq: ADTX) This Morning—Tuesday, June 9, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get (ADTX) On Your Radar While It’s Still Early…
June 9, 2026 Take an Early Look at (Nasdaq: ADTX) Because it Has Less Than 850K Shares Available Dear Reader, At Street Ideas, we pay close attention when a lesser-known Nasdaq company starts lining up with a fast-growing market, peer-reviewed validation, and a real commercial platform. That is why Aditxt, Inc. (Nasdaq: ADTX) has just moved onto our screen this morning. Precision oncology is projected to expand from $133B in 2025 to nearly $339B by 2035, and ADTX’s Ignite Proteomics subsidiary is focused on helping oncologists evaluate cancer therapies at the protein level—an area traditional genomic testing may not fully address. The company’s platform is backed by peer-reviewed research connected to Dana-Farber Cancer Institute, and ADTX recently announced a 10,000-patient registry designed to build a larger real-world clinical dataset. ADTX also appears to be flying under the radar while currently trending below $0.10, which adds another reason this lesser-known Nasdaq name is on our watchlist today. Keep reading to see why ADTX is at the top of our screen this morning—Tuesday, June 9, 2026. But keep in mind, ADTX has less than 850K shares listed as available to the public. When public floats are that small, the potential exists for big moves if demand begins to shift. At the same time, short-term technical indicators, including RSI, suggest ADTX may be approaching what some market watchers consider “oversold” territory. That combination could make ADTX a name worth watching today. 
It's not often we come across a little-known Nasdaq company with a Medicare-reimbursed oncology platform, active revenue generation, and a major new registry announcement all developing simultaneously. Here's a closer look at the behind ADTX.What Does Aditxt Actually Do?
Aditxt, Inc. is a life sciences platform company focused on accelerating promising health innovations. Its flagship asset is Ignite Proteomics, a CLIA-certified, CAP-accredited subsidiary operating a Reverse Phase Protein Array (RPPA) platform in clinical oncology. The RPPA assay quantifies 32 phospho- and total-protein biomarkers directly from tumor biopsy material — telling oncologists not just what genes are present, but whether the signaling pathways targeted by specific therapies are actually switched on inside a patient's tumor right now. That distinction is the core of Ignite's value proposition. Genomics tells you what could happen. Functional proteomics tells you what is happening. With the rapid expansion of targeted cancer therapeutics — antibody-dr-ug conjugates (ADCs), immune checkpoint inhibitors, precision agents — physicians increasingly need to know whether a patient's tumor is functionally expressing the protein targets these therapies require. Standard genomic testing often cannot answer that question. Ignite's RPPA platform is designed specifically to provide that answer, from a single biopsy specimen, in a CLIA-certified, Medicare-reimbursed clinical workflow. Every test result informs a real physician making a real therapy selection decision for a real patient — that is the commercial reality ADTX is operating in today, not a future projection. ADTX acquired Ignite in March 2026, bringing the precision oncology platform fully under the Aditxt umbrella as a key part of its oncology strategy. 
Ignite operates as a fully integrated subsidiary within ADTX's oncology initiatives, and it brought with it an established Medicare PLA code, active collaborations with leading cancer research institutions, and a commercial testing operation already generating revenue. The Market Potential
Third-party market research cited by ADTX pegs the global cancer profiling market at approximately $14B. Ignite has identified roughly $3B in serviceable market potential specifically among patients eligible for ADC therapies and other targeted cancer treatments — the fastest-growing segment of the oncology therapeutics market. The global precision oncology market is projected to grow from $133.06B in 2026 to $317.16B by 2034 at an 11.47% CAGR, and the U.S. alone accounts for a substantial portion of that growth. What makes Ignite's commercial position particularly distinctive is that it has already cleared the hardest hurdle in diagnostics: Medicare reimbursement. Ignite holds a Proprietary Laboratory Analyses (PLA) code with a reimbursement rate of approximately $2,200 per test. That infrastructure — CLIA-certified lab, CAP accreditation, Medicare billing pathway — represents years of regulatory and operational work that most diagnostics startups have not completed. It also means ADTX can scale test volume without first having to fight a reimbursement battle that derails many diagnostics companies before they reach commercial momentum. Clinical Validation and the 10,000-Patient Registry
The science behind ADTX's platform is not theoretical. In April 2026, a peer-reviewed study led by investigators at Dana-Farber Cancer Institute was published in npj Precision Oncology, a Nature journal. The study evaluated outcomes in metastatic breast cancer patients treated with trastuzumab deruxtecan (T-DXd, marketed as Enhertu® by AstraZeneca and Daiichi Sankyo) and assessed multiple quantitative HER2-related assays. Standard HER2 IHC testing showed limited predictive value in certain matched biomarker sub-cohorts. Ignite's RPPA platform — the only commercially available multiplex assay evaluated in the study — demonstrated meaningful predictive value for patient outcomes. That is an independent, peer-reviewed result from one of the world's preeminent cancer research institutions — not a company-sponsored white paper. Beyond Dana-Farber, Ignite has an active collaboration with Vanderbilt University Medical Center on breast cancer immuno-oncology biomarker discovery, and a separate partnership with Inova Health to analyze up to 600 tumor samples from patients with late-stage gastrointestinal cancers — results feeding directly into Inova's Molecular Tumor Board for real-time treatment decisions. On June 8, 2026, ADTX announced that Ignite is launching a prospective oncology registry enrolling up to 10,000 patients. The registry pairs the RPPA platform with structured clinical outcomes tracking across ADC and immunotherapy regimens. The initiative is expected to generate an estimated $13M for Ignite over the course of the agreement — and will produce a real-world functional proteomics dataset at a scale never before assembled in oncology diagnostics. 7 Reasons ADTX Just Landed At The Top Of Our Screen—Tuesday, June 9, 2026…
1. Under The Radar: ADTX appears to be flying under the radar while currently trending below $0.10, adding another angle for readers watching lesser-known Nasdaq companies.
2. Low Float: With fewer than 850K shares listed as available to the public, ADTX’s small float could have the potential for big moves if demand begins to shift. 3. Technical Setup: Short-term technical indicators, including RSI, suggest ADTX may be approaching what some market watchers consider "oversold" territory, a condition that is often monitored for signs of a possible change in direction. 4. Registry Launch: ADTX recently announced a prospective oncology registry expected to enroll up to 10,000 patients, creating a significant new source of real-world clinical data. 5. Peer-Reviewed Data: Research involving ADTX's Ignite Proteomics platform was published in npj Precision Oncology, a Nature journal, following work led by investigators at Dana-Farber Cancer Institute. 6. Growing Market: ADTX is participating in precision oncology, a market projected to expand from approximately $133B in 2026 to more than $317B by 2034 according to market research cited by the company. 7. Commercial Operations: Unlike many early-stage healthcare companies, ADTX's oncology subsidiary is already operating a commercial testing business that is generating revenue today. Get (ADTX) On Your Radar While It’s Still Early…
Some companies make headlines after everyone is already paying attention. Others begin checking important boxes long before they become widely discussed. Between its low float, commercial oncology platform, new 10,000-patient registry, peer-reviewed validation, and growing presence in precision oncology, ADTX is becoming a name we're watching very closely. We have all eyes on ADTX right now. Pull up ADTX this morning and see what has our attention. And don't wander too far—another Street Ideas update could be on the way very shortly. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
